“The Applicant has conducted repeat dose toxicity studies in cynomolgus monkeys with weekly doses administered by subcutaneous injection for up to 26 weeks, followed by a treatment-free recovery period of up to 21 weeks”
✓ VerifiedFDA multi-discipline review, p. 205Source ↗
Pivotal GLP studies
Cynomolgus monkey weekly SC repeat-dose studies up to 26 weeks with up to 21-week recovery
“The Applicant has conducted repeat dose toxicity studies in cynomolgus monkeys with weekly doses administered by subcutaneous injection for up to 26 weeks, followed by a treatment-free recovery period of up to 21 weeks”
✓ VerifiedFDA multi-discipline review, p. 205Source ↗
Route in tox
Subcutaneous and intravenous
“Intravenous and subcutaneous routes of administration were explored.”